Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to demonstrate efficacy of 1 mg Sarizotan HCl b.i.d. after 12 weeks and after 24 weeks (maintenance of efficacy) in the treatment of dyskinesia in Parkinson's disease.
Critère d'inclusion
- Treatment-Associated Dyskinesia in Parkinson's Disease